NextCure (NXTC) Competitors $0.40 -0.07 (-15.63%) Closing price 07/11/2025 03:59 PM EasternExtended Trading$0.43 +0.04 (+9.62%) As of 07/11/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock NXTC vs. RENB, KLRS, BLUE, ADVM, VRCA, DTIL, AADI, ATRA, RNXT, and VTVTShould you be buying NextCure stock or one of its competitors? The main competitors of NextCure include Renovaro (RENB), Kalaris Therapeutics (KLRS), bluebird bio (BLUE), Adverum Biotechnologies (ADVM), Verrica Pharmaceuticals (VRCA), Precision BioSciences (DTIL), Aadi Bioscience (AADI), Atara Biotherapeutics (ATRA), RenovoRx (RNXT), and vTv Therapeutics (VTVT). These companies are all part of the "pharmaceutical products" industry. NextCure vs. Its Competitors Renovaro Kalaris Therapeutics bluebird bio Adverum Biotechnologies Verrica Pharmaceuticals Precision BioSciences Aadi Bioscience Atara Biotherapeutics RenovoRx vTv Therapeutics Renovaro (NASDAQ:RENB) and NextCure (NASDAQ:NXTC) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, risk, earnings, profitability, dividends, valuation and analyst recommendations. Is RENB or NXTC more profitable? Renovaro's return on equity of -60.38% beat NextCure's return on equity.Company Net Margins Return on Equity Return on Assets RenovaroN/A -60.38% -47.04% NextCure N/A -70.16%-58.10% Which has higher earnings and valuation, RENB or NXTC? Renovaro is trading at a lower price-to-earnings ratio than NextCure, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRenovaroN/AN/A-$88.43M-$0.77-0.35NextCureN/AN/A-$55.65M-$1.76-0.22 Do analysts rate RENB or NXTC? NextCure has a consensus target price of $3.50, indicating a potential upside of 786.08%. Given NextCure's stronger consensus rating and higher probable upside, analysts plainly believe NextCure is more favorable than Renovaro.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Renovaro 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00NextCure 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Do insiders & institutionals have more ownership in RENB or NXTC? 71.4% of Renovaro shares are owned by institutional investors. Comparatively, 42.7% of NextCure shares are owned by institutional investors. 21.7% of Renovaro shares are owned by company insiders. Comparatively, 17.9% of NextCure shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the media favor RENB or NXTC? In the previous week, Renovaro and Renovaro both had 3 articles in the media. NextCure's average media sentiment score of 1.93 beat Renovaro's score of 0.22 indicating that NextCure is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Renovaro 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral NextCure 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Which has more volatility & risk, RENB or NXTC? Renovaro has a beta of 0.51, indicating that its stock price is 49% less volatile than the S&P 500. Comparatively, NextCure has a beta of 1.06, indicating that its stock price is 6% more volatile than the S&P 500. SummaryNextCure beats Renovaro on 7 of the 12 factors compared between the two stocks. Get NextCure News Delivered to You Automatically Sign up to receive the latest news and ratings for NXTC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NXTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NXTC vs. The Competition Export to ExcelMetricNextCureMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$13.13M$2.97B$5.62B$9.10BDividend YieldN/A2.39%5.24%4.00%P/E Ratio-0.2220.7128.1320.27Price / SalesN/A288.39428.6398.72Price / CashN/A42.8637.4658.16Price / Book0.177.638.045.49Net Income-$55.65M-$55.05M$3.18B$250.45M7 Day Performance-9.61%8.43%3.62%4.78%1 Month Performance-39.26%5.42%4.05%7.67%1 Year Performance-76.06%2.03%30.00%16.43% NextCure Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NXTCNextCure4.5655 of 5 stars$0.40-15.6%$3.50+786.1%-75.2%$13.13MN/A-0.2290Positive NewsAnalyst UpgradeGap DownHigh Trading VolumeRENBRenovaro1.9337 of 5 stars$0.29-1.3%N/A-81.4%$50.38MN/A-0.3820News CoverageKLRSKalaris TherapeuticsN/A$2.67+1.9%N/AN/A$49MN/A0.00110BLUEbluebird bio1.5832 of 5 stars$4.97flat$44.60+797.4%N/A$48.67M$103.95M-0.13520ADVMAdverum Biotechnologies4.582 of 5 stars$2.15-7.3%$23.80+1,007.0%-67.4%$48.47M$1M-0.34190Positive NewsVRCAVerrica Pharmaceuticals4.5079 of 5 stars$0.53+1.4%$8.00+1,409.1%-90.5%$48.34M$7.57M-0.4440News CoverageGap DownDTILPrecision BioSciences4.2789 of 5 stars$4.20-2.3%$47.00+1,019.0%-54.6%$47.68M$68.70M-2.09200Gap DownAADIAadi Bioscience0.4713 of 5 stars$1.93+1.6%$1.67-13.6%+31.3%$47.67M$25.07M-0.8540ATRAAtara Biotherapeutics4.5506 of 5 stars$7.72-3.0%$17.75+129.9%-9.1%$47.45M$128.94M-2.08330Positive NewsRNXTRenovoRx2.4068 of 5 stars$1.32+2.7%$7.25+451.3%+9.8%$46.81M$40K-3.296Positive NewsVTVTvTv Therapeutics1.6233 of 5 stars$15.00+3.5%$35.50+136.7%-17.0%$46.29M$1.02M-4.989Positive News Related Companies and Tools Related Companies RENB Competitors KLRS Competitors BLUE Competitors ADVM Competitors VRCA Competitors DTIL Competitors AADI Competitors ATRA Competitors RNXT Competitors VTVT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NXTC) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NextCure, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NextCure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NXTC Stock Alerts